

**Pediatrics Certificate**

---

**ACPE Activity Number(s):**

- 0204-0000-20-745-H01-P
- 0204-0000-20-746-H05-P
- 0204-0000-20-747-H01-P
- 0204-0000-20-748-H01-P
- 0204-0000-20-749-H08-P
- 0204-0000-20-750-H01-P
- 0204-0000-20-751-H01-P
- 0204-0000-20-752-H01-P
- 0204-0000-20-753-H01-P

**Release Date:** November 18, 2020

**Expiration Date:** November 18, 2023

**Activity Type:** Application-based

**CE Credit Hour(s):** 27 hours/9 modules

**Activity Fee:** \$445.00/\$545.00 member/non-member

**Accreditation for Pharmacists**

---



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

**Target Audience**

---

This activity is intended for pharmacists responsible for the care of pediatric patients, or who have an interest in learning more about pediatric pharmacy practice.

**Activity Overview**

---

This self-guided, online program will provide 27 hours of ACPE continuing education for pharmacists, incorporating recorded presentations, worksheets, and readings.

The 9 modules are designed to provide focused education on pediatrics, beginning with the unique approach to caring for and assessing a pediatric patient, then progressing to greater depth into the most commonly treated pediatric conditions and disorders seen in acute care and outpatient settings. Upon completion of all the modules, learners should be proficient in caring for a pediatric patient.

**Learning Objectives and Schedule of Activities**

---

Activity CE Information	Title, Description and Learning Objectives
<b>ACPE #: 0204-0000-20-745-H01-P</b>	<b>Title: Introduction to Pediatrics</b>
<b>CE Hours: 3.5</b>	<b>Faculty:</b>
<b>Activity Type: Application-based</b>	<ul style="list-style-type: none"><li>• Lea S. Eiland, Pharm.D., BCPPS, BCPS, FASHP, FPPA</li></ul>

	<ul style="list-style-type: none"> <li>• <b>Rachel Meyers, Pharm.D., BCPS, BCPPS, FPPA</b></li> <li>• <b>Kelly S. Bobo, Pharm.D., MBA, BCPS, BCPPS</b></li> </ul> <p>This activity describes how to assess and plan care for a pediatric patient, including the fundamental differences between pediatric and adult patients related to pharmacokinetics/pharmacodynamics, dosing strategies, sterile and non-sterile compounding, patient communication, drug information resources, and medication administration devices.</p> <p><b>Learning Objectives:</b></p> <ul style="list-style-type: none"> <li>• Compare and contrast an assessment of a pediatric patient to an adult patient.</li> <li>• Design a communication plan for a pediatric patient.</li> <li>• Recognize normal growth, lab values, and vital signs for a pediatric patient.</li> <li>• Apply principles of pharmacokinetic changes during growth while assessing medication orders for pediatric patients.</li> <li>• Calculate creatinine clearance for a pediatric patient.</li> <li>• Use resources for answering medication questions related to pediatrics, pregnancy, and lactation.</li> <li>• Calculate and double check a weight-based or body surface area-based dose for a pediatric patient.</li> <li>• Identify common dosage formulation issues for pediatric patients.</li> <li>• Discuss pediatric specific concepts and challenges related to sterile and non-sterile compounding.</li> <li>• Identify appropriate devices and techniques to ensure safe medication administration and adherence in pediatric patients.</li> </ul>
<p><b>ACPE #: 0204-0000-20-746-H05-P</b></p> <p><b>CE Hours: 1</b></p> <p><b>Activity Type: Application-based</b></p>	<p><b>Title: Medication Safety</b></p> <p><b>Faculty:</b></p> <ul style="list-style-type: none"> <li>• <b>Lisa T. Thames, Pharm.D., BCPS</b></li> </ul> <p>This activity provides strategies for risk mitigation and safe use of medications and technology in pediatric patients.</p> <p><b>Learning Objectives:</b></p>

	<ul style="list-style-type: none"> <li>• Differentiate risk factors that lead to adverse drug events in pediatric patients.</li> <li>• Apply risk mitigation strategies to improve patient safety in pediatric patients.</li> <li>• Identify methods to optimize healthcare technology for safe care of pediatric patients.</li> </ul>
<p><b>ACPE #: 0204-0000-20-747-H01-P</b></p> <p><b>CE Hours: 3.75</b></p> <p><b>Activity Type: Application-based</b></p>	<p><b>Title: Fluids, Electrolytes, and Nutrition</b></p> <p><b>Faculty:</b></p> <ul style="list-style-type: none"> <li>• <b>M. Petrea Cober, Pharm.D., BCNSP, BCPPS, FASPEN</b></li> <li>• <b>Kathleen Gura, Pharm.D., BCNSP, FASHP, FPPA, FASPEN, FMSHP</b></li> </ul> <p>This activity details appropriate fluid use, enteral and parenteral nutrition use, and fluid calculation strategies for pediatric patients.</p> <p><b>Learning Objectives:</b></p> <ul style="list-style-type: none"> <li>• Describe pediatric intravenous fluids appropriate for a pediatric patient.</li> <li>• Recognize the signs and symptoms of pediatric dehydration.</li> <li>• Differentiate characteristics of various peripheral and central venous access devices.</li> <li>• Compute a pediatric patient’s maintenance intravenous fluid rate and potential fluid deficit.</li> <li>• Design a fluid replacement regimen for a pediatric dehydration patient.</li> <li>• Explain why neonates and infants require a specialized amino acid solution when receiving parenteral nutrition.</li> <li>• Discuss complications and limitations patients may experience with parenteral nutrition.</li> <li>• Identify monitoring parameters for a pediatric patient receiving parenteral nutrition.</li> <li>• Recommend an appropriate feeding route and regimen.</li> <li>• Explain how to administer medications to a patient with an enteral feeding tube.</li> </ul>
<p><b>ACPE #: 0204-0000-20-748-H01-P</b></p> <p><b>CE Hours: 3</b></p> <p><b>Activity Type: Application-based</b></p>	<p><b>Title: Neonatology and Extracorporeal Membrane Oxygenation</b></p> <p><b>Faculty:</b></p> <ul style="list-style-type: none"> <li>• <b>Amy P. Holmes, Pharm.D., BCPPS</b></li> </ul>

	<ul style="list-style-type: none"> <li>• <b>Sherry Luedtke, Pharm.D., FPPA</b></li> <li>• <b>Katherine I. Lemming, Pharm.D.</b></li> </ul> <p>This activity describes care of healthy neonatal patients and commonly-seen diseases of the neonate, as well as medication considerations during extracorporeal membrane oxygenation.</p> <p><b>Learning Objectives:</b></p> <ul style="list-style-type: none"> <li>• Summarize physiologic differences in newborns including pharmacokinetic and pharmacodynamic differences.</li> <li>• Identify standard interventions recommended / required at birth along with the rationale for each.</li> <li>• Apply strategies utilized in prevention of bronchopulmonary dysplasia.</li> <li>• Compare treatment options for each of the following: apnea of prematurity, necrotizing enterocolitis, respiratory distress of the newborn, and patent ductus arteriosus.</li> <li>• Describe unexpected complications encountered in newborns.</li> <li>• Develop pharmacotherapy recommendations for the management of complications in the newborn.</li> <li>• Summarize pharmacokinetic and pharmacodynamic changes that occur during extracorporeal membrane oxygenation.</li> </ul>
<p><b>ACPE #: 0204-0000-20-749-H08-P</b></p> <p><b>CE Hours: 2.25</b></p> <p><b>Activity Type: Application-based</b></p>	<p><b>Title: Pain and Sedation</b></p> <p><b>Faculty:</b></p> <ul style="list-style-type: none"> <li>• <b>Jamie L. Miller, Pharm.D., BCPS, BCPPS, FPPA</b></li> <li>• <b>Pete N. Johnson, Pharm.D., BCPS, BCPPS, FPPA, FCCM</b></li> </ul> <p>This activity describes assessment of pain and judicious use of medications for pain and sedation in neonatal and pediatric patients.</p> <p><b>Learning Objectives:</b></p> <ul style="list-style-type: none"> <li>• Select the most appropriate scale to assess pain and sedation when given a neonatal patient case.</li> <li>• Recommend the most appropriate intervention/agent according to the six-step approach to analgesia in the neonatal patient when given a patient case.</li> </ul>

	<ul style="list-style-type: none"> <li>• Compare and contrast the short- and long-term effects in preterm neonates with the use of morphine, fentanyl, dexmedetomidine, and midazolam for sedation during mechanical ventilation.</li> <li>• Compare and contrast scales used to assess pain &amp; sedation in critically ill infants and children.</li> <li>• Select a first-line opioid infusion (i.e., morphine, hydromorphone, fentanyl, remifentanyl) for a critically ill child when given a patient case.</li> <li>• Identify the advantages &amp; disadvantages of the use of midazolam, dexmedetomidine, and ketamine as a first-line sedative infusion when given a patient case.</li> </ul>
<p><b>ACPE #: 0204-0000-20-750-H01-P</b></p> <p><b>CE Hours: 3.25</b></p> <p><b>Activity Type: Application-based</b></p>	<p><b>Title: Cardiac and Pulmonary Diseases</b></p> <p><b>Faculty:</b></p> <ul style="list-style-type: none"> <li>• <b>E. Zachary Ramsey, Pharm.D., BCPPS</b></li> <li>• <b>Hailey Collier, Pharm.D., BCPS, BCPPS</b></li> <li>• <b>Kimberly J. Novak, Pharm.D., BCPS, BCPPS, FPPA</b></li> </ul> <p>This activity discusses pathophysiology, assessment, therapeutic interventions, and monitoring parameters in the care of common pediatric cardiac and pulmonary issues, including congenital heart diseases, pulmonary hypertension, Kawasaki disease, advanced life support, cystic fibrosis, asthma, and the common cold.</p> <p><b>Learning Objectives:</b></p> <ul style="list-style-type: none"> <li>• Describe the pathophysiology of congenital heart diseases and pulmonary hypertension.</li> <li>• Identify pharmacokinetic and pharmacodynamic facets of medications used to treat congenital heart diseases and pulmonary hypertension.</li> <li>• Explain place-in-therapy of medications used to treat congenital heart diseases and pulmonary hypertension.</li> <li>• Differentiate place-in-therapy of presented medications for patients with congenital heart diseases and pulmonary hypertension.</li> <li>• Identify the clinical criteria necessary for the diagnosis of Kawasaki disease.</li> </ul>

	<ul style="list-style-type: none"> <li>• Determine the appropriate therapeutic interventions for Kawasaki disease based on patient-specific presentation.</li> <li>• Describe the structured approach for the assessment and treatment of pediatric patients requiring advanced life support.</li> <li>• Identify the appropriate therapeutic interventions based on patient-specific presentation.</li> <li>• Provide recommendations for the diagnosis, evaluation, and treatment of hypertension in a pediatric patient.</li> <li>• List medications used to treat common chronic complications of cystic fibrosis.</li> <li>• Develop an antibiotic plan for treatment of a cystic fibrosis pulmonary exacerbation in an outpatient and inpatient setting.</li> <li>• Apply the stepwise approach for chronic asthma management to a patient case.</li> <li>• Design an acute treatment regimen for an asthma exacerbation.</li> <li>• Identify cough and cold medications that should be avoided in pediatric patients.</li> </ul>
<p><b>ACPE #: 0204-0000-20-751-H01-P</b></p> <p><b>CE Hours: 3.25</b></p> <p><b>Activity Type: Application-based</b></p>	<p><b>Title: Infectious Diseases</b></p> <p><b>Faculty:</b></p> <ul style="list-style-type: none"> <li>• <b>Kathryn G. Merkel, Pharm.D., BCPS, BCIDP, BCPPS</b></li> <li>• <b>Lea S. Eiland, Pharm.D., BCPPS, BCPS, FASHP, FPPA</b></li> <li>• <b>Chasity M. Shelton, Pharm.D., FCCP, BCPS, BCPPS</b></li> </ul> <p>This activity covers infectious disease topics in pediatrics including immunizations, sepsis, UTI, acute otitis media, bronchiolitis, influenza, pneumonia, meningitis, common skin and bone infections, <i>Clostridium difficile</i>, and candidemia, and as well as principles of antimicrobial stewardship.</p> <p><b>Learning Objectives:</b></p> <ul style="list-style-type: none"> <li>• Analyze the impact of the components that comprise an antimicrobial stewardship program.</li> <li>• Develop an immunization care plan for a hospitalized neonate, child, and adolescent.</li> </ul>

	<ul style="list-style-type: none"> <li>• Justify empiric antimicrobial treatment recommendations for sepsis and urinary tract infections.</li> <li>• Discuss issues in treating pediatric patients presenting with COVID-19.</li> <li>• Differentiate risk factors, common etiologies, and the clinical presentation of a pediatric patient with acute otitis media, bronchiolitis, influenza, pneumonia, or meningitis.</li> <li>• Develop a treatment plan for a pediatric patient with acute otitis media, bronchiolitis, influenza, pneumonia, or meningitis.</li> <li>• Develop an appropriate antimicrobial therapy regimen for common skin / soft tissue and/or bone / joint infections when given a pediatric patient case.</li> <li>• Compare recommended antimicrobial regimens for Clostridium difficile infections in pediatric patients to adult patients using the 2017 Clinical Practice Guidelines for Clostridium difficile infection in adults and children.</li> <li>• Develop an antifungal treatment regimen in a critically ill pediatric patient with candidemia.</li> </ul>
<p><b>ACPE #: 0204-0000-20-752-H01-P</b></p> <p><b>CE Hours: 4</b></p> <p><b>Activity Type: Application-based</b></p>	<p><b>Title: Neurological / Psychiatric, Gastrointestinal, and Endocrine Disorders</b></p> <p><b>Faculty:</b></p> <ul style="list-style-type: none"> <li>• <b>Justin W. Cole, Pharm.D., BCPS</b></li> <li>• <b>Julie A. Dopheide, Pharm.D., BCPP, FASHP</b></li> <li>• <b>Jill A. Morgan, Pharm.D., BCPPS, BCPS</b></li> <li>• <b>Michelle Condren, Pharm.D., BCPPS, CDCES, AE-C, FPPA</b></li> </ul> <p>This activity covers common neurological and psychiatric disorders seen in pediatric practice, including epilepsy, migraine, cerebral palsy, ADHD, autism spectrum disorder, depression, bipolar disorder, and schizophrenia; further, GI and endocrine disorders such as GERD, constipation, Crohn’s disease, ulcerative colitis, and diabetes mellitus are discussed.</p> <p><b>Learning Objectives:</b></p> <ul style="list-style-type: none"> <li>• Compare drug therapies used for the treatment of common neurologic conditions in pediatric patients, including common epilepsy syndromes.</li> </ul>

	<ul style="list-style-type: none"> <li>• Identify first-line medications for the treatment of acute neurologic conditions in children, including status epilepticus.</li> <li>• Compare drug therapies used for the treatment of common neurologic conditions in pediatric patients, including migraine headaches.</li> <li>• Identify first-line medications for the treatment of acute neurologic conditions in children, including migraine headaches.</li> <li>• Compare drug therapies used for the treatment of common neurologic conditions in pediatric patients including cerebral palsy.</li> <li>• Recommend pharmacotherapy regimens with good patient tolerability to manage symptoms in children with attention-deficit hyperactivity disorder or autism spectrum disorder.</li> <li>• Apply recommendations for the safe and effective use of antidepressants to manage depression, anxiety and PTSD symptoms in children and adolescents.</li> <li>• Compare the strength of evidence and tolerability of antipsychotics and mood stabilizers for managing bipolar disorder and schizophrenia in children and adolescents.</li> <li>• Design a treatment regimen for an infant presenting with GERD.</li> <li>• Calculate the replacement fluid needs for a pediatric patient with acute diarrhea.</li> <li>• Create a treatment plan for a pediatric patient with functional constipation.</li> <li>• Design a monitoring plan for agents used in ulcerative colitis and Crohn’s disease in pediatric patients.</li> <li>• Develop a treatment plan for a child with type 1 or type 2 diabetes mellitus.</li> <li>• Select appropriate devices for treating and monitoring a child with type 1 diabetes mellitus.</li> </ul>
<p><b>ACPE #: 0204-0000-20-753-H01-P</b></p> <p><b>CE Hours: 3</b></p> <p><b>Activity Type: Application-based</b></p>	<p><b>Title: Pharmacogenomics, Hematology and Oncology Conditions, and Toxicology</b></p> <p><b>Faculty:</b></p> <ul style="list-style-type: none"> <li>• <b>Hyun Kim, Pharm.D.</b></li> <li>• <b>Jennifer Thackray, Pharm.D., BCPS, BCPPS</b></li> <li>• <b>Joshua Elder, Pharm.D., BCPS, BCOP</b></li> <li>• <b>Alexandra R. Funk, Pharm.D., DABAT</b></li> </ul>



This activity describes pharmacogenomic principles applicable in pediatrics; chemotherapy regimens used commonly in pediatric oncology; management of acute lymphoblastic leukemia and sickle cell disease; and poisonings, toxidromes, and antidotes commonly seen in pediatrics.

**Learning Objectives:**

- Describe pediatric-specific principles of pharmacogenomics.
- List currently available clinical pharmacogenomics guidelines that have implications for pediatrics.
- Apply available clinical pharmacogenomics guidelines to a sample patient case.
- Evaluate chemotherapy regimens used commonly in pediatric oncology for indication, dosing, common toxicities, supportive care and monitoring parameters.
- Describe the clinical presentation, pharmacotherapeutic plan and common toxicities of a pediatric patient with acute lymphoblastic leukemia.
- Design a maintenance chemotherapy treatment plan for a pediatric patient with acute lymphoblastic leukemia based on pharmacogenomic patient data.
- Apply evidence-based recommendations in the management of patients with sickle cell disease.
- Identify novel therapeutic treatment strategies for patients with sickle cell disease.
- Analyze anticoagulation treatment strategies in the management of pediatric venous thromboembolism.
- Recognize common toxidromes and antidotes.
- Develop treatment regimens for poisonings.

## Faculty Information

---

**Kelly S. Bobo, Pharm.D., M.B.A., BCPS, BCPPS**

Clinical Pharmacy Manager  
PGY1 and PGY2 Residency Program Director  
Le Bonheur Children's Hospital  
Assistant Professor  
The University of Tennessee  
Health Science Center, Department of Clinical Pharmacy and Translational Science  
Memphis, Tennessee

**M. Petrea Cober, Pharm.D., BCNSP, BCPPS, FASPEN**

Clinical Coordinator, NICU  
Akron Children's Hospital  
Professor of Pharmacy Practice  
Northeast Ohio Medical University, College of Pharmacy  
Akron, Ohio

**Hailey Collier, Pharm.D., BCPS, BCPPS**

Clinical Pharmacy Specialist, Pediatric Cardiology and Heart Transplant  
The Children's Hospital of Philadelphia  
Philadelphia, Pennsylvania

**Justin W. Cole, Pharm.D., BCPS**

Chair and Associate Professor of Pharmacy Practice  
Cedarville University School of Pharmacy  
Cedarville, Ohio

**Michelle Condren, Pharm.D., BCPPS, CDCES, AE-C, FPPA**

Professor and Vice-Chair for Research, Department of Pediatrics  
University of Oklahoma School of Community Medicine  
Tulsa, Oklahoma

**Julie A. Dopheide, Pharm.D., BCPP, FASHP**

Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences  
University of Southern California School of Pharmacy and Keck School of Medicine  
Los Angeles, California

**Joshua Elder, Pharm.D., BCPS, BCOP**

Clinical Specialist, Pediatric Hematology, Oncology, and Stem Cell Transplant  
Director, PGY2 Oncology Pharmacy Residency  
Norton Children's Hospital  
Louisville, Kentucky

**Lea S. Eiland, Pharm.D., BCPPS, BCPS, FASHP, FPPA**

Clinical Professor and Associate Department Head of Pharmacy Practice  
Auburn University Harrison School of Pharmacy  
Auburn, Alabama

**Alexandra R. Funk, Pharm.D., DABAT**

Clinical Toxicologist and Director  
Central Ohio Poison Center  
Nationwide Children's Hospital  
Columbus, Ohio

**Kathleen Gura, Pharm.D., BCNSP, FASHP, FPPA, FASPEN, FMSHP**

Manager, Pharmacy Clinical Research Programs  
Clinical Pharmacist, Division of Gastroenterology, Hepatology and Nutrition  
Boston Children's Hospital  
Assistant Professor of Pediatrics  
Harvard Medical School  
Boston, Massachusetts

**Amy P. Holmes, Pharm.D., BCPPS**

Neonatal Intensive Care Unit Pharmacist  
Brenner Children's Hospital  
Wake Forest Baptist Medical Center  
Winston Salem, North Carolina

**Hyun Kim, Pharm.D.**

Clinical Pharmacist, Clinical Pharmacogenomics Service  
Boston Children's Hospital  
Boston, Massachusetts

**Peter N. Johnson, Pharm.D., BCPS, BCPPS, FPPA, FCCM**

Associate Professor of Pharmacy Practice  
University of Oklahoma College of Pharmacy  
Oklahoma City, Oklahoma

**Katherine I. Lemming, Pharm.D.**

Clinical Pharmacy Specialist, Pediatric Cardiology – Cardiac Intensive Care  
Department of Pharmacy  
Texas Children's Hospital  
Houston, Texas

**Sherry Luedtke, Pharm.D., FPPA**

Associate Professor, Pharmacy Practice  
Jerry H. Hodge School of Pharmacy  
Texas Tech University Health Science Center  
Amarillo, Texas

**Kathryn G. Merkel, Pharm.D., BCPS, BCIDP, BCPPS**

Clinical Pharmacy Manager  
St. David's South Austin Medical Center  
Austin, Texas

**Rachel Meyers, Pharm.D., BCPS, BCPPS, FPPA**

Clinical Associate Professor  
Ernest Mario School of Pharmacy  
Rutgers University  
Pediatric Clinical Pharmacist  
Saint Barnabas Medical Center  
Livingston, New Jersey

**Jamie Miller, Pharm.D., BCPS, BCPPS, FPPA**

Associate Professor  
University of Oklahoma College of Pharmacy  
Oklahoma City, Oklahoma

**Jill A. Morgan, Pharm.D., BCPPS, BCPS**

Professor and Chair  
University of Maryland School of Pharmacy  
Baltimore, Maryland

**Kimberly J. Novak, Pharm.D., BCPS, BCPPS, FPPA**

Advanced Patient Care Pharmacist, Pediatric and Adult Cystic Fibrosis  
Director, PGY2 Pharmacy Residency-Pediatrics  
Nationwide Children's Hospital  
Department of Pharmacy  
Columbus, Ohio

**E. Zachary Ramsey, Pharm.D., BCPPS**

Clinical Pharmacy Specialist in Pediatric Cardiology  
Children's Hospital of Philadelphia  
Philadelphia, Pennsylvania

**Chasity M. Shelton, Pharm.D., FCCP, BCPS, BCPPS**

Assistant Dean  
Student Success and Associate Professor  
Department of Clinical Pharmacy & Translational Science  
The University of Tennessee Health Science Center  
Memphis, Tennessee

**Jennifer Thackray, Pharm.D., BCPS, BCPPS**

Pediatric Oncology Clinical Pharmacy Specialist  
Memorial Sloan Kettering Cancer Center  
New York, New York

**Lisa T. Thames, Pharm.D., BCPS**

Assistant Director, Inpatient Pharmacy Services  
Director, Education Programs  
UF Health Shands Hospital  
Gainesville, Florida

## Disclosures

---

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP requires that all individuals in a position to control the content of this activity disclose financial relationships with ACCME-defined commercial entities. An individual has a relevant financial relationship if he or she (or spouse/domestic partner) has a financial relationship, in any amount, occurring in the past 12 months with a commercial entity whose products or services will be discussed in the activity.

In this activity, only the individual(s) below have a relevant financial relationship.

- M. Petrea Cober, Pharm.D., BCNSP, BCPPS, FASPEN
  - Consultant: Baxter
  - Consultant: B. Braun Medical Inc.
  - Consultant: Fresenius Kabi USA, LLC.
- Kathleen Gura, Pharm.D., BCNSP, FASHP, FPPA, FASPEN, FMSHP
  - Member, pharmaceutical advisory board / consultant: B. Braun Medical Inc., Pfizer, and Alcresta Therapeutics, Inc.
  - Member, scientific advisory board / consultant: Fresenius Kabi USA, LLC., Baxter, and Otsuka America Pharmaceutical, Inc.
  - Research support: Fresenius Kabi USA, LLC, NorthSea Therapeutics B.V.

All other ASHP staff, planners, faculty, reviewers, and subject matter experts report no financial relationships relevant to this activity.

## Methods and CE Requirements

---

This online activity consists of a combined total of 9 learning modules. Pharmacists are eligible to receive a total of 27 hours of continuing education credit by completing all 9 modules within this certificate program.

Participants must participate in the entire activity, complete the evaluation and all required components to claim continuing pharmacy education credit online at ASHP eLearning Portal (<http://elearning.ashp.org>). Follow the prompts to claim credit and view your statement of credit within 60 days after completing the activity.

### **Important Note – ACPE 60 Day Deadline:**

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions!

To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully

before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.

## System Technical Requirements

---

System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. Users should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.